Cover Image
市場調查報告書

EpiCast Report:全球老年癡呆症的免疫學的預測

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 262491
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:全球老年癡呆症的免疫學的預測 EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2023
出版日期: 2015年03月16日 內容資訊: 英文 82 Pages
簡介

全球的60歲以上的人口佔的癡呆症患者的比率為3.9%,老年癡呆症的患病者的比率,美國為9.7%,歐洲為4.4%,發展中國家為3.4%。全球各國老年癡呆症的患病人數今後將劇增。全球主要9個國家的患病人數,從2012年的1253萬人,2022年以年平均(年複合成長率)3.35%的迅速速度增加到1672萬人。

本報告提供全球主要9個國家(美國·德國·法國·義大利·西班牙·英國·日本·中國·印度)的克隆氏症的發病情形與今後預測相關分析,血脂異常症的特徵,及各國的詳細內容,今後10年的發病數量·患病人數的預測值等等的調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 免疫學

  • 風險要素和合併症
    • 老年癡呆症的家族病史提高到7.5倍風險
    • ApoE ε4 等位基因使老年癡呆症的風險提高3倍
    • 心血管疾病的風險因素,使老年癡呆症的風險倍增
    • 65歲以上老年癡呆症的發病數量·患病人數每5歲倍增
    • 糖尿病男性的發病風險提高2倍,女性的情況微增
    • 女性的發病風險比起男性高1.5倍
    • 輕度認知功能障礙(MCI)提高老年癡呆症的風險
    • 憂鬱症使老年癡呆症的風險增加到三倍,但也有是單純疾病階段的情況
    • 老年癡呆症患者的最大70%也受困於焦慮症
    • 精神病和躁動,是老年癡呆症患者的一般併發症
  • 全球各國趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本
    • 中國
    • 印度
  • 預測手法
    • 利用的資訊來源
    • 預測的前提條件與手法
    • 未利用的資訊來源
  • 免疫學的預測(今後10年)
    • 老年癡呆症的患病人數
    • 各年齡層的患病人數
    • 男女的患病人數
    • 以年齡標準化的患病人數
  • 議論
    • 免疫學趨勢的相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER010-15

AD is an irreversible, neurodegenerative brain disease of the elderly, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity. Similar to AD, mild cognitive impairment (MCI) is also a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.

To forecast the total prevalent cases of AD in adults ages =60 years in the 9MM during the forecast period (2013-2023), GlobalData epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD. Similarly, to forecast the total prevalent cases of MCI in the 9MM, GlobalData's epidemiologists selected country-specific studies that defined MCI as a "slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia." Additionally, GlobalData epidemiologists kept the forecast methodology consistent across the 9MM in order to allow for a meaningful comparison of the total prevalent cases between the markets.

GlobalData epidemiologists forecast that by 2023, there will be approximately 17.38 million total prevalent cases of AD across the 9MM covered in this analysis. GlobalData epidemiologists expect a 34.3% increase in the total prevalent cases of AD in the 9MM over the next decade. Similarly, GlobalData epidemiologists forecast that the total prevalent cases of MCI in the 9MM will increase from 82.25 million cases in 2013 to 108.41 million cases in 2013 at a decadal growth rate of 31.80%.

Scope

  • The Alzheimer's disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). The series also includes a 10-year epidemiological forecast for the total prevalent cases of AD segmented by sex, age, and severity in these markets. In addition, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age in these markets.
  • The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
  • Identify the percentage of AD prevalent cases by severity and identify the number of cases with MCI.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports
  • 2.2. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. A family history of Alzheimer's increases the risk of developing the disease by 7.5 times
    • 3.2.2. The APOE ε4 allele triples the risk for AD
    • 3.2.3. Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life
    • 3.2.4. The incidence and prevalence of AD double every five years after age 65 years
    • 3.2.5. Diabetes doubles the risk of AD in men, but only marginally affects the risk in women
    • 3.2.6. Women are 1.5 times more likely to develop AD than men
    • 3.2.7. Depression triples the risk for AD, and is the most common comorbidity
    • 3.2.8. Up to 70% of AD patients also suffer from anxiety
    • 3.2.9. Psychosis and agitation are common comorbidities in Alzheimer's patients
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
    • 3.3.4. China
    • 3.3.5. India
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Sources Not Used
  • 3.5. Epidemiology Forecast (2013-2023)
    • 3.5.1. Total Prevalent Cases of AD
    • 3.5.2. Age-Specific Total Prevalent Cases of AD
    • 3.5.3. Sex-Specific Total Prevalent Cases of AD
    • 3.5.4. Age-Standardized Total Prevalence of AD
    • 3.5.5. Total Prevalent Cases of AD, by Severity
    • 3.5.6. Total Prevalent Cases of MCI
    • 3.5.7. Age-Specific Total Prevalent Cases of MCI
    • 3.5.8. Sex-Specific Total Prevalent Cases of MCI
    • 3.5.9. Age-Standardized Total Prevalence of MCI
  • 3.6. Discussion
    • 3.6.1. Conclusions Regarding the Epidemiological Trends
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologist
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for AD
  • Table 2: DSM-III-R Criteria for the Diagnosis of Dementia
  • Table 3: NINCDS-ADRDA Criteria for the Diagnosis of AD
  • Table 4: 9MM, Epidemiological Sources for AD Total Prevalence Data
  • Table 5: 9MM, Epidemiological Sources for AD Total Prevalence Data, Based on Severity
  • Table 6: 9MM, Epidemiological Sources for MCI Total Prevalence Data
  • Table 7: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of AD
  • Table 8: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of MCI
  • Table 9: 9MM, Total Prevalent Cases of AD, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Table 10: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N (Row %), 2013
  • Table 11: 9MM, Total Prevalent Cases of AD, by Sex, Age ≥ 60 Years, N (Row %), 2013
  • Table 12: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N (Row %), 2013
  • Table 13: 9MM, Total Prevalent Cases of MCI, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Table 14: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N (Row %), 2013
  • Table 15: 9MM, Total Prevalent Cases of MCI, by Sex, Age ≥60 Years, N (Row %), 2013

List of Figures

  • Figure 1: 9MM, Total Prevalent Cases of AD, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Figure 2: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N, 2013
  • Figure 3: 9MM, Total Prevalent Cases of AD, by Sex, Age ≥60 Years, N, 2013
  • Figure 4: 9MM, Age-Standardized Total Prevalence of AD, Age ≥60 Years, Men and Women, %, 2013
  • Figure 5: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N, 2013
  • Figure 6: 9MM, Total Prevalent Cases of MCI, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Figure 7: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N, 2013
  • Figure 8: 9MM, Total Prevalent Cases of MCI, by Sex, Age ≥60 Years, N, 2013
  • Figure 9: 9MM, Age-Standardized Total Prevalence of MCI, Age ≥60 Years, Men and Women, %, 2013
Back to Top